ABBV logo

ABBV AbbVie Inc.

New York Stock Exchange · Drug Manufacturers - General · Healthcare

$286.20
+2.66 (+0.94%)

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaqu…

Market Cap: $505.89Bwww.abbvie.com

Price

$286.20+7.68%
$248.78$264.20$279.61$295.03
Aug 25Nov 20

Social Signal Score

50
5d
50
8 mentions
-2.3%
30d
51
56 mentions
+0.2%
60d
50
155 mentions
+8.0%
90d
51
227 mentions
+8.2%
marketaux: 15 · news: 167 · rss: 45

Analyst Ratings

44 analysts
Buyconsensus
Strong Buy 0Buy 31Hold 12Sell 1Strong Sell 0
Avg price target$316.87+10.7%
Low $275Median $320High $349
Current Consensus

52-week range

$197.38$295.03
Last close
$286.20
Off 52w high
-3.0%
200-day average
$242.45
vs 200-day
+18.0%

Revenue

$17.40B+156.09%
$6.54B$10.16B$13.78B$17.40B
Dec 2016Sep 2026

Analyst Estimates

FY2025
$9.94
$9.89–$10.05
15 analysts
FY2026
$14.01+41% YoY
$13.93–$14.17
16 analysts
FY2027
$16.26+16% YoY
$15.49–$16.57
16 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert A. Michael
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
57,000
Beta
0.28
Country
US
Piotroski score
8 / 9 (Strong)
Altman Z-score
2.63
www.abbvie.com